Header Logo

Connection

Shabir Madhi to Immunization, Secondary

This is a "connection" page, showing publications Shabir Madhi has written about Immunization, Secondary.
Connection Strength

4,729
  1. Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
    View in: PubMed
    Score: 0,924
  2. Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):1011-1019.
    View in: PubMed
    Score: 0,907
  3. Safety of COVID-19 booster dose: is the juice worth the squeeze? Lancet Infect Dis. 2023 10; 23(10):1097-1099.
    View in: PubMed
    Score: 0,826
  4. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. S Afr Med J. 2011 Nov 28; 101(12):879-83.
    View in: PubMed
    Score: 0,371
  5. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007 Mar 22; 25(13):2451-7.
    View in: PubMed
    Score: 0,259
  6. Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV. AIDS. 2023 12 01; 37(15):2305-2310.
    View in: PubMed
    Score: 0,211
  7. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
    View in: PubMed
    Score: 0,176
  8. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2019; 15(3):658-668.
    View in: PubMed
    Score: 0,152
  9. Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines. Expert Rev Vaccines. 2019 01; 18(1):95-104.
    View in: PubMed
    Score: 0,150
  10. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
    View in: PubMed
    Score: 0,140
  11. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status. Medicine (Baltimore). 2017 Jan; 96(2):e5881.
    View in: PubMed
    Score: 0,132
  12. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013 Aug; 32(8):889-97.
    View in: PubMed
    Score: 0,104
  13. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine. 2011 Apr 18; 29(18):3372-3.
    View in: PubMed
    Score: 0,088
  14. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
    View in: PubMed
    Score: 0,057
  15. Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
    View in: PubMed
    Score: 0,055
  16. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother. 2021 06 03; 17(6):1770-1778.
    View in: PubMed
    Score: 0,043
  17. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Vaccine. 2017 08 03; 35(34):4321-4329.
    View in: PubMed
    Score: 0,034
  18. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015 Jul 17; 29(11):1345-54.
    View in: PubMed
    Score: 0,030
  19. Safety of licensed vaccines in HIV-infected persons: a systematic review protocol. Syst Rev. 2014 Sep 11; 3:101.
    View in: PubMed
    Score: 0,028
  20. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. Pediatr Infect Dis J. 2011 Feb; 30(2):125-30.
    View in: PubMed
    Score: 0,022
  21. Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine. 2010 Feb 17; 28(7):1677-83.
    View in: PubMed
    Score: 0,020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.